The lancet. HIV · 2020
Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pintye Jillian, Davey Dvora L Joseph, Wagner Anjuli D, John-Stewart Grace, Baggaley Rachel, Bekker Linda-Gail, Celum Connie, Chi Benjamin H, Coates Thomas J, Groves Allison K, Haberer Jessica E, Heffron Renee, Kinuthia John, Matthews Lynn T, McIntyre James A, Moodley Dhayendre, Mofenson Lynne M, Mugo Nelly, Mujugira Andrew, Myer Landon, Shoptaw Steven, Stranix-Chibanda Lynda, Baeten Jared M, PrEP in Pregnancy Working Group
Аннотация
Pregnancy is a high-risk period for HIV acquisition in African women, and pregnant women who become acutely infected with HIV account for up to a third of vertical HIV transmission cases in African settings. To protect women and eliminate vertical transmission, WHO recommends offering oral pre-exposure prophylaxis (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women with a substantial risk of HIV acquisition. PrEP implementation for pregnant and post-partum women lags behind implementation for other high-risk populations. Unique considerations for PrEP implementation arise during pregnancy and post partum, including the integration of provider training with clinical delivery and monitoring of PrEP exposure and outcomes within existing maternal health systems, yet scarce implementation data are available to generate evidence in this context.